MedPath

cytarabine

Cytarabine Injection(For Intravenous, Intrathecal and Subcutaneous Use Only)

Approved
Approval ID

9bc7f6c2-4b16-449b-b383-76106540206c

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

May 22, 2023

Manufacturers
FDA

Sagent Pharmaceuticals

DUNS: 080579617

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

cytarabine

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code25021-223
Application NumberANDA211938
Product Classification
M
Marketing Category
C73584
G
Generic Name
cytarabine
Product Specifications
Route of AdministrationINTRAVENOUS, INTRATHECAL, SUBCUTANEOUS
Effective DateMay 22, 2023
FDA Product Classification

INGREDIENTS (4)

waterInactive
Code: 059QF0KO0R
Classification: IACT
cytarabineActive
Quantity: 100 mg in 1 mL
Code: 04079A1RDZ
Classification: ACTIB
hydrochloric acidInactive
Code: QTT17582CB
Classification: IACT
sodium hydroxideInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

cytarabine - FDA Drug Approval Details